Radiation proctitis after iodine‐125 low‐dose‐rate prostate brachytherapy utilizing SpaceOAR hydrogel
International Journal of Urology · 2024
DOI: 10.1111/iju.15504 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Masashi Morita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Showa University Koto Toyosu Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms, Proctitis, Radiation Injuries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Objective
We retrospectively evaluated the efficacy of combining the SpaceOAR (SOAR) hydrogel with prostate brachytherapy, using colonoscopy findings to assess for radiation proctitis.
Methods
Among 731 patients undergoing iodine‐125 low‐dose‐rate prostate brachytherapy (LDR‐BT), SOAR was utilized in 394 patients (53.9%). Colonoscopy was performed for 97 patients (13.3%) to assess the presence, location, condition, and treatment of radiation proctitis. We also investigated treatment factors associated with the occurrence of radiation proctitis.
Results
Radiation proctitis was observed in 57 patients (7.8%) and 17 (2.3%) were treated with argon plasma coagulation (APC). The incidence of radiation proctitis was 12.2% in the non‐SOAR and 4.1% in the SOAR group ( p < 0.001). In the non‐SOAR group, the incidence of radiation proctitis was 6.6% for LDR‐BT monotherapy and increased to 22.0% when combined with external beam radiation therapy (EBRT) ( p = 0.001). However, in the SOAR group, these rates significantly decreased to 3.3% and 5.7% for monotherapy and combination therapy, respectively ( p = 0.035, p < 0.001). With SOAR, inflammation was observed directly above the DL in most patients (87.5%), and only one patient (6.3%) required APC. The absence of SOAR ( p < 0.001, HR = 0.29) and the concurrent use of EBRT ( p = 0.018, HR = 2.87) were identified as significant risk factors for the occurrence of radiation proctitis.
Conclusion
The use of SOAR significantly reduced the incidence of radiation proctitis in patients undergoing LDR‐BT monotherapy and combined EBRT. Inflammation primarily occurred directly above the DL; further examination is necessary to clarify its cause.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Showa University Koto Toyosu Hospital, Tokyo, Japan.
- Digestive Diseases Center, Showa University Koto Toyosu Hospital, Tokyo, Japan.
- Department of Urology, Showa University School of Medicine, Tokyo, Japan.
- Department of Surgery, JABSOM, University of Hawaii, Honolulu, Hawaii, USA.
Zitieren
APA
Morita, M., Hiramatsu, A., Nishimura, K., Yanagida, W., Nakamura, S., Yamatoya, J., Noguchi, T., Tanabe, M., Fukagai, T., & Lederer, J. L. (2024). Radiation proctitis after iodine‐125 low‐dose‐rate prostate brachytherapy utilizing SpaceOAR hydrogel. International Journal of Urology. https://doi.org/10.1111/iju.15504
Vancouver
Morita M, Hiramatsu A, Nishimura K, Yanagida W, Nakamura S, Yamatoya J, et al. Radiation proctitis after iodine‐125 low‐dose‐rate prostate brachytherapy utilizing SpaceOAR hydrogel. International Journal of Urology. 2024. doi:10.1111/iju.15504
BibTeX
@article{Morita2024,
author = {Morita, Masashi and Hiramatsu, Aya and Nishimura, Kota and Yanagida, Wahei and Nakamura, Saori and Yamatoya, Jin and Noguchi, Tetsuo and Tanabe, Mayo and Fukagai, Takashi and Lederer, John L},
title = {Radiation proctitis after iodine‐125 low‐dose‐rate prostate brachytherapy utilizing SpaceOAR hydrogel},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15504}
}
EUVIMED